4 results
To determine the benefit of Dimebon as compared to placebo on the primary measure of cognition and memory, the Alzheimer*s Disease Assessment Scale * cognitive subscale (ADAS-cog); andTo determine the benefit of Dimebon as compared to placebo on the…
To evaluate the long-term safety and tolerability of Dimebon in AD patients who have successfully completed 26 weeks of blinded treatment in the CONNECTION Study (DIM14) (hereafter referred to as *CONNECTION*).
To determine the safety and efficacy of Dimebon in patients with mild to moderate Huntington Disease
Primary Objective: The objective of this study is to asses whether or not the use of four implants in the augmented maxilla is as effective on the improvement of the patient*s oral functioning measured with the MFIQ as the use of six…